Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | S-531011 |
Trade Name | |
Synonyms | S 531011|S531011 |
Drug Descriptions |
S-531011 is an antibody that targets CCR8, potentially resulting in antibody-dependent cellular cytotoxicity against regulatory T-cells expressing CCR8 and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2021;9). |
DrugClasses | CCR8 Antibody 9 |
CAS Registry Number | NA |
NCIT ID | C185418 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Pembrolizumab + S-531011 | Pembrolizumab S-531011 | 0 | 1 |
S-531011 | S-531011 | 0 | 1 |
S-531011 + unspecified PD-1 antibody | S-531011 unspecified PD-1 antibody | 0 | 0 |